1-哌嗪羧酸丙酯 | 37008-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-哌嗪羧酸丙酯
• 英文名称: propyl piperazine-1-carboxylate
• CAS: 37008-22-3
• 化学式: C₈H₁₆N₂O₂
• 分子量: 172.227
• InChiKey: IGXBNWXKQPCCCJ-UHFFFAOYSA-N

物化性质

• 沸点：
  254.9±15.0 °C(Predicted)
• 密度：
  1.048±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-哌嗪羧酸丙酯 在 氧化亚氮 、 sodium methylate 作用下， 以 甲醇 为溶剂， 以58%的产率得到sodium 1-[4-(n-propoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate
  参考文献：
  名称：

  Antitumor Activity of JS-K [O²-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O²-Aryl Diazeniumdiolates in Vitro and in Vivo

  摘要：

  The literature provides evidence that metabolic nitric oxide ( NO) release mediates the cytotoxic activities ( against human leukemia and prostate cancer xenografts in mice) of JS-K, a compound of structure R2N-(O)=NO-Ar for which R2N is 4-(ethoxycarbonyl) piperazin-1-yl and Ar is 2,4-dinitrophenyl. Here we present comparative data on the potencies of JS-K and 41 other O-2-arylated diazeniumdiolates as inhibitors of HL-60 human leukemia cell proliferation, as well as in the NCI 51-cell-line screen for six of them. The data show JS-K to be the most potent of the 42 in both screens and suggest that other features of its structure and metabolism besides NO release may contribute importantly to its activity. Results with control compounds implicate JS-K's arylating ability, and the surprisingly low IC50 value of the N-(ethoxycarbonyl) piperazine byproduct of NO release suggests a role for the R2N moiety. In addition to the above-mentioned in vivo activities, JS-K is shown here to be carcinostatic in a rat liver cancer model.

  DOI：

  10.1021/jm060022h
• 作为产物：
  描述：

  Piperazine-1,4-dicarboxylic acid propyl ester benzyl ester 在 钯 氢气 、 乙醇 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 1-哌嗪羧酸丙酯
  参考文献：
  名称：

  HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS

  摘要：

  本发明涉及式I的化合物，其中R1；R2；Z；A；B；D；Q；J；V；G和M具有所述声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常适用于存在不希望的血小板ADP受体P2Y12激活的情况，或者用于治疗或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制剂。

  公开号：

  US20110021537A1

文献信息

• [EN] 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE 6-PHÉNYL OU 6-(PYRIDIN-3-YL)INDAZOLE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2015112445A1

  公开（公告）日：2015-07-30

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书所述，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制造这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use
  申请人：ABBVIE INC.

  公开号：US20160376240A1

  公开（公告）日：2016-12-29

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书中所定义，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制备这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3
  作者：Chuhui Huang、Si Si Liew、Grace R. Lin、Anders Poulsen、Melgious J. Y. Ang、Brian C. S. Chia、Sin Yin Chew、Zekui P. Kwek、John L. K. Wee、Esther H. Ong、Priya Retna、Nithya Baburajendran、Rong Li、Weixuan Yu、Xiaoying Koh-Stenta、Anna Ngo、Sravanthy Manesh、Justina Fulwood、Zhiyuan Ke、Hwa Hwa Chung、Sugunavathi Sepramaniam、Xin Hui Chew、Nurul Dinie、May Ann Lee、Yun Shan Chew、Choon Bing Low、Vishal Pendharkar、Vithya Manoharan、Susmitha Vuddagiri、Kanda Sangthongpitag、Joma Joy、Alex Matter、Jeffrey Hill、Thomas H. Keller、Klement Foo

  DOI：10.1021/acsmedchemlett.9b00170

  日期：2019.6.13

  overexpression is associated with multiple human cancers. A novel class of tetrahydroacridine compounds which inhibit SMYD3 through a covalent mechanism of action is identified. Optimization of these irreversible inhibitors resulted in the discovery of 4-chloroquinolines, a new class of covalent warheads. Tool compound 29 exhibits high potency by inhibiting SMYD3′s enzymatic activity and showing antiproliferative

  SMYD3是一种可调节基因转录的组蛋白甲基转移酶，其过表达与多种人类癌症有关。鉴定了通过共价作用机理抑制SMYD3的一类新型的四氢ac啶化合物。这些不可逆抑制剂的优化导致了4-氯喹啉的发现，这是一类新型的共价战斗部。工具化合物29通过抑制SMYD3的酶促活性并在3D细胞培养中显示出对HepG2的抗增殖活性，从而具有很高的效力。我们的发现表明，对SMYD3的共价抑制可能通过影响表达水平而对SMYD3生物学产生影响，这值得进一步探索。
• [EN] COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER ET ÉPIGÉNÉTIQUE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2017061957A1

  公开（公告）日：2017-04-13

  Compounds For Inhibition Of Cancer and Epigenesis The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.

  抑制癌症和表观遗传学的化合物。本发明涉及式(I)的喹啉和5,6,7,8-四氢喹啉，其中Z1、Z2、X、R1至R8和Y的定义如说明书中所述，或其药学上可接受的形式或前药，它们是甲基转移酶的抑制剂，如蛋白赖氨酸甲基转移酶，特别是SMYD3。本发明还涉及它们的制备方法，含有这些化合物的药物组合物，以及这些化合物在治疗涉及、与或与具有甲基转移酶活性/功能的酶或通过未指定/多靶向机制相关的紊乱/疾病/疾病的用途。
• NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT
  申请人：PEGORARO Stefano

  公开号：US20100197640A1

  公开（公告）日：2010-08-05

  The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.

  本发明涉及具有化学式（I）的新型磺胺酰基苯基脲类化合物或其生理上可接受的盐或衍生物，适用于治疗由原虫引起的感染，特别是由疟原虫引起的非并发或严重疟疾。